US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.89 ▼-1.02% TSLA $378.69 ▲+2.18% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% SNDK $1,704.16 ▼-0.92% AAPL $332.89 ▼-0.24%
FinancialContent

Liquidia Corporation - Common Stock (NQ:LQDA)

27.64 -1.00 (-3.49%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Liquidia Corp (LQDA) Stock: A High-Growth Pick Meeting the Minervini Trend Template ↗
Liquidia (LQDA) stock shows a powerful technical uptrend and explosive 1,121% revenue growth, aligning with the high-momentum Minervini strategy. 
Via Chartmill
News headline image
Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Expert Outlook: Liquidia Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
What's Next: Liquidia's Earnings Preview ↗
 
Via Benzinga
News headline image
Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
12 Analysts Have This To Say About Liquidia ↗
 
Via Benzinga
News headline image
Liquidia Corp (NASDAQ:LQDA) Smashes Q3 2025 Estimates with Stellar YUTREPIA Launch ↗
Liquidia's Q3 2025 results crushed expectations with $54.3M revenue, driven by the successful launch of YUTREPIA. The stock surged as the company moves toward profitability. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Insmed Catapults While IBD 50's Argenx Creeps Higher On Bullish Reports ↗
Insmed stock surged early Thursday as Argenx stock rose more moderately. The top-notch biotech companies beat third-quarter calls. 
Via Investor's Business Daily
News headline image
Earnings Preview For Liquidia ↗
 
Via Benzinga
News headline image
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
What 5 Analyst Ratings Have To Say About Liquidia ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Liquidia Announces Poster Presentations at the Pulmonary Hypertension Professional Association (PHPN) Symposium
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With It ↗
The company sells Tyvaso, a treatment for lung diseases. On Tuesday, Tyvaso showed promise, again, in a chronic condition. 
Via Investor's Business Daily
News headline image
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia Analysts Raise Their Forecasts Following Q2 Results ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Is Liquidia Stock Trading Higher On Tuesday? ↗
Liquidia Q2 sales hit $8.84 million after Yutrepia launch; PH-ILD study shows stable tolerability and improved walking distance at week 16. 
Via Benzinga
News headline image
Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It ↗
The company is working through a patent battle that could seriously hamper sales of its new drug. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? ↗
Shares are trading at a 25-year high ahead of what could be the first approval for a drug with a massive pipeline in front of it. 
Via Investor's Business Daily
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
From Liquidia Technologies, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >